NEW MJ NEWS

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET.

A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Biome Grow Inc. (BIOIF) (BIO.CN) Quadruples Revenue, Triples Gross Profit in Q2, 2019

Biome Grow Quadruples Revenue, Triples Gross Profit in Q2, 2019   Biome…

Neptune Wellness Solutions Inc. (NEPT) Announces Next Phase of Strategic Review Process

Neptune Announces Next Phase of Strategic Review Process Neptune Wellness Solutions Inc.…

Aphria Inc. (APHQF) German subsidiary, Nuuvera Deutschland, acquires interest in Berlin-based Shöneberg Hospital

Aphria’s German subsidiary, Nuuvera Deutschland, acquires interest in Berlin-based Shöneberg Hospital Aphria…

Organigram Holdings Inc. (OGI) Provides Corporate Update

Organigram Provides Corporate Update Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the…